Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
293.9 EUR | +1.48% | -.--% | -.--% |
05-14 | Swiss Market Index Edges Up Ahead of Inflation Report | MT |
05-14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 43.4 and 34.64 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 42.49B | - | ||
+29.77% | 49.46B | B- | ||
+1.00% | 42.58B | B | ||
-5.26% | 29.09B | C | ||
+13.68% | 26.61B | B- | ||
-22.99% | 18.64B | B | ||
+8.22% | 13.16B | B+ | ||
+32.41% | 12.55B | C+ | ||
-1.62% | 11.98B | C+ | ||
+24.01% | 12.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LONN Stock
- LO3 Stock
- Ratings Lonza Group AG